Messenger RNA levels of podocyte-associated proteins in subjects with different degrees of glucose tolerance with or without nephropathy

BMC Nephrology

Francisco V Veronese³  Sane Pereira²  Mariane dos Santos²  Gabriel Joelsons²  Patricia G Rodrigues²  Fernando Gerchman¹  Luis H Canani¹  Jonathan Fraportti do Nascimento² 

[1]Division of Endocrinology, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil

[2]Post Graduate Program in Medicine: Medical Sciences, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil

[3]Division of Nephrology, Hospital de Clínicas de Porto Alegre, Ramiro Barcelos 2350, Porto Alegre, RS ZIP 90035-003, Brazil

关键词: TRPC6;    Nephrin;    Podocyte;    Prediabetes;    Diabetic nephropathy;   

Others  :  1082825
DOI  :  10.1186/1471-2369-14-214

 received in 2013-07-29, accepted in 2013-10-04,  发布年份 2013

【 摘 要 】

Background

To investigate gene expression of podocyte-specific proteins in urine of diabetes and prediabetes subjects and the association of these proteins with albuminuria.

Methods

Fifteen controls, 19 prediabetes, and 67 diabetes subjects were included. Messenger RNA of nephrin, podocin, podocalyxin, synaptopodin, TRPC6, alpha-actinin-4, and TGF-β₁ were measured using RT-PCR. Podocyte marker expression was correlated with albuminuria, glycemic control, and renal function. The diagnostic performance of the genes used to detect increased albuminuria was assessed using ROC curves and Poisson regressions.

Results

Podocyte marker expression was significantly higher in diabetic subjects. Urinary nephrin was correlated with increasing levels of albuminuria; risk of albuminuria increased by 20% for every one-unit increase in the log10 of nephrin mRNA. Nephrinuria was found in 53%, 71%, and 90% of normo-, micro-, and macroalbuminuric diabetes subjects, respectively (p = 0.023). Urinary nephrin, podocalyxin, TRPC6, podocin, and alpha actinin-4 were correlated with glycemic control and albuminuria but not with renal function.

Conclusions

Diabetes subjects had higher urinary mRNA levels of podocyte proteins than nondiabetic subjects, even the normoalbuminuric patients. Nephrinuria was correlated with diabetic nephrophathy stage and predicted pathological albuminuria. Urinary mRNA levels of podocyte markers of prediabetic subjects did not differ from controls.

【 授权许可】

   
2013 do Nascimento et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Sesso RC, Lopes AA, Thomé FS, Lugon JR, Santos DR: 2010 report of the Brazilian dialysis census. J Bras Nefrol 2011, 33:442-447.
• [2]Diez-Sampedro A, Lenz O, Fornoni A: Podocytopathy in diabetes: a metabolic and endocrine disorder. Am J Kidney Dis 2011, 58:637-646.
• [3]Wolf G, Chen S, Ziyadeh FN: From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. Diabetes 2005, 54:1626-1634.
• [4]Toyoda M, Najafian B, Kim Y, Caramori ML, Mauer M: Podocyte detachment and reduced glomerular capillary endothelial fenestration in human type 1 diabetic nephropathy. Diabetes 2007, 56:2155-2160.
• [5]Susztak K, Raff AC, Schiffer M, Bottinger EP: Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 2006, 55:225-233.
• [6]Wendt TM, Tanji N, Guo J, Kislinger TR, Qu W, Lu Y, et al.: RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 2003, 162:1123-1137.
• [7]Schrijvers BF, De Vriese AS, Flyvbjerg A: From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocr Rev 2004, 25:971-1010.
• [8]Hara M, Yanagihara T, Kihara I, Higashi K, Fujimoto K, Kajita T: Apical cell membranes are shed into urine from injured podocytes: a novel phenomenon of podocyte injury. J Am Soc Nephrol 2005, 16:408-416.
• [9]Petermann A, Floege J: Podocyte damage resulting in podocyturia: a potential diagnostic marker to assess glomerular disease activity. Nephron Clin Pract 2007, 106:61-66.
• [10]Skoberne A, Konieczny A, Schiffer M: Glomerular epithelial cells in the urine: what has to be done to make them worthwhile? Am J Physiol Renal Physiol 2009, 296:230-241.
• [11]Barisoni L, Schnaper W, Koop JB: Advances in the biology and genetics of the podocytopathies. Arch Pathol Lab Med 2009, 133:201-216.
• [12]Möller CC, Wei C, Altintas MM, Li J, Greka A, Ohse T, et al.: Induction of TRPC6 channel in acquired forms of proteinuric kidney disease. J Am Soc Nephrol 2007, 18:29-36.
• [13]Chen S, Jim B, Ziyadeh FN: Diabetic nephropathy and transforming growth factor-beta: transforming our view of glomerulosclerosis and fibrosis build-up. Semin Nephrol 2003, 23:532-543.
• [14]Nakamura T, Ushiyama C, Suzuki S, Hara M, Shimada N, Ebihara I, et al.: Urinary excretion of podocytes in patients with diabetic nephropathy. Nephrol Dial Transplant 2000, 15:1379-1383.
• [15]Wang G, Lai FM, Lai KB, Chow KM, Li KT, Szeto CC: Messenger RNA expression of podocyte-associated molecules in the urinary sediment of patients with diabetic nephropathy. Nephron Clin Pract 2007, 106:169-179.
• [16]Ng DP, Tai BC, Tan E, Leong H, Nurbaya S, Lim XL, et al.: Nephrinuria associates with multiple renal traits in type 2 diabetes. Nephrol Dial Transplant 2011, 26:2508-2514.
• [17]Xing Y, Ye S, Hu Y, Chen Y: Podocyte as a potential target of inflammation: role of hydrochloride pioglitazone in type 2 diabetics. Endocrinol Pract 2012, 18:493-498.
• [18]Wang G, Lai FM, Lai KB, Chow KM, Kwan BC, Li PK, et al.: Urinary messenger RNA expression of podocyte-associated molecules in patients with diabetic nephropathy treated by angiotensin-converting enzyme inhibitor and angiotensin receptor blocker. Eur J Endocrinol 2008, 158:317-322.
• [19]American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care 2010, 33:62-69.
• [20]Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI 3rd, et al.: A new equation to estimate glomerular filtration rate. Ann Intern Med 2009, 150:604-612.
• [21]Abramson JH: WINPEPI (PEPI-for-Windows): computer programs for epidemiologists. Epidemiol Perspect Innov 2004, 1:6. BioMed Central Full Text
• [22]Marshall SM: The podocyte: a potential therapeutic target in diabetic nephropathy? Curr Pharma Des 2007, 13:2713-2720.
• [23]Doublier S, Salvidio G, Lupia E, Ruotsalainen V, Verzola D, Deferrari G, et al.: Nephrin expression is reduced in human diabetic nephropathy: evidence for a distinct role for glycated albumin and angiotensin II. Diabetes 2003, 52:1023-1030.
• [24]Verzola D, Gandolfo MT, Ferrario F, Rastaldi MP, Villaggio B, Gianiorio F, et al.: Apoptosis in the kidneys of patients with type II diabetic nephropathy. Kidney Int 2007, 72:1262-1272.
• [25]Steffes MW, Schmidt D, McCrery R, Basgen JM: Glomerular cell number in normal subjects and in type 1 diabetic patients. Kidney Int 2001, 59:2104-2113.
• [26]Szeto CC, Lai KB, Chow KM, Szeto CY, Yip TW, Woo KS, et al.: Messenger RNA expression of glomerular podocyte markers in the urinary sediment of acquired proteinuric diseases. Clin Chim Acta 2005, 361:182-190.
• [27]Vogelmann SU, Nelson WJ, Myers BD, Lemley KV: Urinary excretion of viable podocytes in health and renal disease. Am J Physiol Renal Physiol 2003, 285:40-48.
• [28]Zheng M, Lv LL, Ni J, Ni HF, Li Q, Ma KL, et al.: Urinary podocyte-associated mRNA profile in various stages of diabetic nephropathy. PLoS One 2011, 6:20431.
• [29]Dalla Vestra M, Masiero A, Roiter AM, Saller A, Crepaldi G, Fioretto P: Is podocyte injury relevant in diabetic nephropathy? Studies in patients with type 2 diabetes. Diabetes 2003, 52:1031-1035.
• [30]Meyer TW, Bennett PH, Nelson RG: Podocyte number predicts long-term urinary albumin excretion in Pima Indians with Type II diabetes and microalbuminuria. Diabetologia 1999, 42:1341-1344.
• [31]White KE, Bilous RW, Marshall SM, El Nahas M, Remuzzi , Piras GP, et al.: Podocyte number in normotensive type 1 diabetic patients with albuminuria. Diabetes 2002, 51:3083-3089.
• [32]Benigni A, Gagliardini E, Tomasoni S, et al.: Selective impairment of gene expression and assembly of nephrin in human diabetic nephropathy. Kidney Int 2004, 65:2193-2200.
• [33]Jim B, Ghanta M, Qipo A, Fan Y, Chuang PY, Cohen HW, et al.: Dysregulated nephrin in diabetic nephropathy of type 2 diabetes: a cross sectional study. PLoS One 2012, 7:e36041.
• [34]Graham S, Gorin Y, Abboud HE, Ding M, Lee DY, Shi H, et al.: Abundance of TRPC6 protein in glomerular mesangial cells is decreased by ROS and PKC in diabetes. Am J Physiol Cell Physiol 2011, 301:304-315.
• [35]Patäri A, Forsblom C, Havana M, Taipale H, Groop PH, et al.: Nephrinuria in diabetic nephropathy of type 1 diabetes. Diabetes 2003, 52:2969-2974.
• [36]Lemley KV, Blouch K, Abdullah I, Boothroyd DB, Bennett PH, Myers BD, et al.: Glomerular permselectivety at the onset of nephropathy in type 2 diabetes mellitus. J Am Soc Nephrol 2000, 11:2095-2105.
• [37]Kimura M, Toyoda M, Kato M, Kobayashi K, Abe M, Kobayashi T: Expression of alpha-actinin-4 in human diabetic nephropathy. Intern Med 2008, 47:1099-1106.
• [38]Ha TS: High glucose and advanced glycosylated end products affect expression of alpha-actinin-4 in glomerular epithelial cells. Nephrology 2006, 17:57-68.
• [39]Dryer SE, Reiser J: TRPC6 channels and their binding partners in podocytes: role in glomerular filtration and pathophysiology. Am J Physiol Renal Physiol 2010, 299:689-701.
• [40]WuDT BM, Ju W, Mundel P, Böttinger EP: TGFbeta concentration specifies differential signaling profiles of growth arrest/differentiation and apoptosis in podocytes. J Am Soc Nephrol 2005, 16:3211-3221.
• [41]Wahab NA, Schaefer L, Weston BS, Yiannikouris O, Wright A, Babelova A, et al.: Glomerular expression of thrombospondin-1, transforming growth factor beta and connective tissue growth factor at different stages of diabetic nephropathy and their interdependent roles in mesangial response to diabetic stimuli. Diabetologia 2005, 48:2650-2660.
• [42]Langham RG, Kelly DJ, Cox AJ, Thomson NM, Holthöfer H, Pinel N, et al.: Proteinuria and the expression of the podocyte slit diaphragm protein, nephrin, in the diabetic nephropathy: effects of angiotensin converting enzyme I inhibition. Diabetologia 2002, 45:1572-1576.